{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:35:39Z","timestamp":1775615739376,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jhepr.2023.100749","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T20:51:02Z","timestamp":1680727862000},"page":"100749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Innovative approaches to the management of ascites in cirrhosis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-8869","authenticated-orcid":false,"given":"Florence","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100749_bib1","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/ajg.2013.110","volume":"108","author":"Bruno","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100749_bib2","article-title":"Baveno Cooperation: an EASL consortium. Risk of further decompensation\/mortality in patients with cirrhosis and ascites as the first single decompensation event","volume":"4","author":"Balcar","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2023.100749_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41395-018-0185-6","article-title":"Refractory ascites in liver cirrhosis","volume":"114","author":"Adebayo","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100749_bib4","article-title":"Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2023.100749_bib5","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","volume":"75","author":"Engelmann","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2023.100749_bib6","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2021.01.018","article-title":"New clinical and pathophysiological perspectives defining the trajectory of cirrhosis","volume":"75","author":"Jalan","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100749_bib8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100749_bib9","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(19)30736-6","article-title":"Prevention of decompensation in cirrhosis: a new youth for \u03b2 blockers","volume":"393","author":"Levy","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100749_bib10","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100749_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12072-017-9835-9","article-title":"Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding","volume":"12","author":"Abd Elrahim","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2023.100749_bib12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib13","doi-asserted-by":"crossref","first-page":"E1511","DOI":"10.1016\/j.cgh.2021.07.050","article-title":"Non-hemodynamic effects of beta-blockers in decompensated cirrhosis. In search of an ideal marker?","volume":"20","author":"Sharma","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib15","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.14309\/ajg.0000000000001887","article-title":"A\u00a0combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease","volume":"117","author":"Dajti","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100749_bib16","first-page":"S1542","article-title":"The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension","volume":"22","author":"Jachs","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Casulleras M.,et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fern\u00e1ndez","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100749_bib18","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100749_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2020.08.021","article-title":"On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites","volume":"74","author":"Caraceni","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Di Pascoli","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100749_bib21","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sol\u00e0","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib22","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jhep.2022.03.005","article-title":"Long-term albumin treatment in patients with cirrhosis and ascites","volume":"76","author":"Caraceni","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: a unique perspective on the co-management of diabetes mellitus and ascites","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2023.100749_bib24","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.31270","article-title":"Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100749_bib25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.14309\/ajg.0000000000000995","article-title":"Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis","volume":"116","author":"Kalambokis","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100749_bib26","first-page":"795","article-title":"SGLT2 Inhibitors: a new dawn for recurrent\/refractory cirrhotic ascites","volume":"9","author":"Gao","year":"2021","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2023.100749_bib27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100749_bib28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intra-hepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100749_bib29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.dld.2017.06.011","article-title":"Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis","volume":"49","author":"Busk","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2023.100749_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MOG.0000000000000733","article-title":"Advances in cirrhotic cardiomyopathy","volume":"37","author":"Liu","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100749_bib31","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/hep.30934","article-title":"A\u00a0prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse Algorithm","volume":"70","author":"Billey","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100749_bib32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00270-017-1848-1","article-title":"Symptomatic heart failure after transjugular intrahepatic portosystemic shunt placement: incidence, outcomes, and predictors","volume":"41","author":"Modha","year":"2017","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.jhepr.2023.100749_bib33","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/gutjnl-2019-320221","article-title":"Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension","volume":"69","author":"Tripathi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100749_bib34","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cgh.2021.07.018","article-title":"Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension","volume":"20","author":"Boike","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.dld.2016.10.011","article-title":"Consensus conference on TIPS management: techniques, indications, contraindications","volume":"49","author":"Fagiuoli","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2023.100749_bib36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.32596","article-title":"The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: recent evolution and open questions","volume":"77","author":"Deltenre","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100749_bib37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cgh.2018.01.029","article-title":"Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis","volume":"16","author":"Schepis","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib38","article-title":"Controlled under-dilation using novel VIATORR\u00ae controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation","volume":"3","author":"Praktiknjo","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2023.100749_bib39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/M20-0202","article-title":"The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial","volume":"174","author":"Bureau","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2023.100749_bib40","first-page":"4763","article-title":"Recurrence of hepatic encephalopathy after TIPS: effective prophylaxis with combination of lactulose and rifaximin","volume":"10","author":"Seifert","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2023.100749_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000531","volume":"7","author":"de Wit","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100749_bib42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/MEG.0000000000001890","article-title":"Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models","volume":"33","author":"Li","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib43","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2021.01.023","article-title":"Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival","volume":"74","author":"Bettinger","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jhep.2010.08.025","article-title":"Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS","volume":"54","author":"Bureau","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib45","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jhep.2021.04.027","article-title":"External validation of the Freiburg index of post-TIPS survival","volume":"75","author":"Kraglund","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2021.05.042","article-title":"Freiburg index of post-TIPS survival: the first score for individual prediction and a complementary tool for risk stratification","volume":"75","author":"Wang","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100749_bib48","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2017.06.010","article-title":"Alfapump\u00ae system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study","volume":"67","author":"Bureau","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib49","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2012.12.020","article-title":"Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study","volume":"58","author":"Bellot","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00423-015-1356-1","article-title":"Automated low flow pump system for the treatment of refractory ascites: a single-center experience","volume":"400","author":"Thomas","year":"2015","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"10.1016\/j.jhepr.2023.100749_bib51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/apt.14331","article-title":"Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis","volume":"46","author":"Stirnimann","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2023.100749_bib52","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/MEG.0000000000001149","article-title":"Automated low-flow ascites pump in a real-world setting: complications and outcomes","volume":"30","author":"Solbach","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/lt.25724","article-title":"Improvement in quality of life and decrease in large-volume paracentesis requirements with the automated low-flow ascites pump","volume":"26","author":"Wong","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2023.100749_bib54","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1177\/2050640620938525","article-title":"Transjugular intrahepatic portosystemic shunt and alfapump\u00ae system for refractory ascites in liver cirrhosis: outcomes and complications","volume":"8","author":"Will","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2023.100749_bib55","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/apt.15502","article-title":"Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites","volume":"50","author":"Lepida","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2023.100749_bib56","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/lt.24763","article-title":"Effects of alfapump\u2122 system on kidney and circulatory function in patients with cirrhosis and refractory ascites","volume":"23","author":"Sol\u00e0","year":"2017","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2023.100749_bib57","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12876-022-02173-5","article-title":"Consensus care recommendations for alfapump\u00aein cirrhotic patients with refractory or recurrent ascites","volume":"22","author":"Aagaard","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100749_bib58","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s11136-018-1813-8","article-title":"Patients with refractory ascites treated with alfapump\u00ae system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study","volume":"27","author":"Stepanova","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhepr.2023.100749_bib59","first-page":"27","article-title":"Combined treatment of refractory ascites with an alfapump\u00ae plus\u00a0hernia repair in the same surgical session: a retrospective, multicentre, European pilot study in cirrhotic patients","volume":"158","author":"Nguyen-Khac","year":"2021","journal-title":"J\u00a0Visc Surg"},{"key":"10.1016\/j.jhepr.2023.100749_bib60","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.dld.2021.12.007","article-title":"Current treatment options of refractory ascites in liver cirrhosis - a systematic review and meta-analysis","volume":"54","author":"Will","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2023.100749_bib61","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/liv.15337","article-title":"Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump","volume":"42","author":"Stirnimann","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100749_bib62","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4254\/wjh.v14.i7.1344","article-title":"Alfapump\u00ae implantable device in the management of refractory ascites: an update","volume":"14","author":"Weil-Verhoeven","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100749_bib63","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/liv.14042","article-title":"Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis","volume":"39","author":"Reverter","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100749_bib64","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0040-1708806","article-title":"Noninvasive diagnostics for portal hypertension: a comprehensive review","volume":"40","author":"Mandorfer","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2023.100749_bib65","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/hep.31907","article-title":"Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis","volume":"74","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100749_bib66","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41591-018-0138-z","article-title":"De novo NAD(+) biosynthetic impairment in acute kidney injury in humans","volume":"24","author":"Poyan Mehr","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2023.100749_bib67","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/hep.32060","article-title":"Metabolomics to predict acute kidney injury in cirrhosis","volume":"74","author":"Piano","year":"2021","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:30:43Z","timestamp":1762900243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2589555923000800"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100749","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative approaches to the management of ascites in cirrhosis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100749"}}